Blockade of HERG channels by HIV protease inhibitors

Blake D. Anson, Joel G.R. Weaver, Michael J. Ackerman, Omobosola Akinsete, Keith Henry, Craig T. January, Andrew D. Badley

Research output: Contribution to journalArticle

101 Scopus citations

Abstract

The HIV protease inhibitor class of antiretroviral drug causes unpredicted adverse effects by changing elements of normal cellular metabolism. A case of QT prolongation in a patient receiving protease inhibitors made us question whether these drugs might be responsible. We identified 24 patients with QT prolongation or torsade de pointes, or both, associated with protease inhibitors, using the Food and Drug Administration's voluntary adverse event reporting system. Attending physicians thought that protease inhibitors were the most probable cause of these symptoms in 14 of the patients. Drug-induced QT prolongation is usually caused by block of human ether-a-go-go-related gene (HERG) potassium channels, and we showed that lopinavir, nelfinavir, ritonavir, and saquinavir caused dose-dependent block of HERG channels heterologously expressed in HEK293 cells in vitro. We also recorded block by lopinavir of repolarising potassium current (IKr) channels in neonatal mouse cardiac myocytes. Our data show that four protease inhibitors block HERG channels, suggesting that protease inhibitors could predispose individuals to QT prolongation and torsade de pointes.

Original languageEnglish (US)
Pages (from-to)682-686
Number of pages5
JournalLancet
Volume365
Issue number9460
DOIs
StatePublished - Feb 19 2005

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Blockade of HERG channels by HIV protease inhibitors'. Together they form a unique fingerprint.

  • Cite this

    Anson, B. D., Weaver, J. G. R., Ackerman, M. J., Akinsete, O., Henry, K., January, C. T., & Badley, A. D. (2005). Blockade of HERG channels by HIV protease inhibitors. Lancet, 365(9460), 682-686. https://doi.org/10.1016/S0140-6736(05)70936-3